Implications of the paradigm shift in management of <i>Helicobacter pylori</i> infections.

"Dr David Y. Graham is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel Helicobacter pylori therapies and has received research support for culture of H. pylori. He is also a consultant with Janssen Research & Development regarding potential gastrointestinal effects of drugs under development and has collaborated on research projects with American Molecular regarding molecular diagnostics for H. pylori."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr David Y. Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338, which funds the Texas Medical Center Digestive Diseases Center."